Abstracts tagged "inflammation and interleukins (IL)"

Abstract Number: 1810 • 2012 ACR/ARHP Annual Meeting
Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL17A
David Livingston, Sethu Alexander, Julian Bond, Timothy Briggs, Andrew Fraley, Stephen Hale, Tanya Landsman, Richard Martinelli, Kelley Shortsleeves, Nick Terrett and Nathan Walsh, Ensemble Therapeutics, Cambridge, MA
Background/Purpose: : IL17A has been demonstrated to be a key pro-inflammatory cytokine in human rheumatoid arthritis and in several rodent models of arthritis. Synthetic macrocycles…
Abstract Number: 529 • 2012 ACR/ARHP Annual Meeting
The Axis P2X7 Receptor-Inflammasome: A Role in Modulating Inflammatory Response in Primary Sjögren’s Syndrome?
Chiara Baldini¹, Chiara Rossi¹, Eleonora Santini¹, Francesco Ferro¹, Alessia Gallo², Daniela Martini¹, Francesca Sernissi¹, Valentina Donati¹, Camillo Giacomelli¹, Nicoletta Luciano¹, Anna Solini¹ and Stefano Bombardieri¹, ¹Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Sjogren's Clinic, NIDCR, Bethesda, MD
Background/Purpose: The exact cause of exocrine gland dysfunction in primary Sjögren’s syndrome (pSS) has not been fully delineated, but it is thought that both innate…
Abstract Number: 180 • 2012 ACR/ARHP Annual Meeting
Safety of Canakinumab in a Large Cohort of Patients with Cryopyrin-Associated Periodic Syndrome: Results From the ß-Confident Registry
H. Hoffman¹, J. B. Kuemmerle-Deschner², P. Hawkins³, T. van der Poll⁴, Ulrich A. Walker⁵, B. Rauer⁶, J. M. Nebesky⁶ and H. Tilson⁷, ¹University of California at San Diego, San Diego, CA, ²Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ³University College London Medical School, London, United Kingdom, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology, Universitäts-Poliklinik, Felix-Platter Spital, Basel, Switzerland, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷The University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina
Background/Purpose: Cryopyrin-associated periodic syndrome (CAPS) is an extremely rare autoinflammatory disorder associated with overproduction of interleukin-1β (IL-1β). Canakinumab, a fully human, selective, anti-IL-1β monoclonal antibody,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].